Poor remission status, older age, type of anti-myeloma therapy and anti-CD38-directed therapy, in particular, have consistently been identified as additional factors impacting vaccination response [13,14,15,16,17,18,19]. This evidence concerns the gene CD38 and plasma cell myeloma.